FDA Accelerated Approval Program Tightens Postmarket Commitments Under 2025 FDORA Section 3210 Reporting

Manufacturers holding accelerated approvals face a sharper compliance posture in 2026, as the FDA's Accelerated Approval Program now operates under expanded reporting obligations introduced by Section 3210 of FDORA, with the Accelerated Approval Coordinating Council's 2025 activity report now publicly available. For QA directors and regulatory affairs leads, the practical weight falls on postmarket commitments, confirmatory trial timelines, surrogate endpoint validation, and the procedural framework FDA can invoke to withdraw a product that fails to demonstrate clinical benefit.

The program's foundational mechanism remains unchanged: approval is granted on the basis of a surrogate endpoint, a laboratory measurement, radiographic image, or physical sign thought to predict clinical benefit, allowing earlier market access for drugs addressing serious conditions with unmet medical need. Confirmatory trials remain mandatory. Where those trials verify clinical benefit, FDA converts the designation to traditional approval. Where they do not, regulatory procedures for market withdrawal are available and have been used.

Three therapeutic categories carry the bulk of active accelerated approvals: cancer indications, infectious disease (excluding vaccines), and non-malignant hematological and neurological disorders. Each category maintains separate tracking for ongoing approvals, verified clinical benefit conversions, and withdrawals. For plant heads and supply-chain leads, the distinction between ongoing and verified-benefit status has direct implications for labeling, distribution controls, and any restricted-distribution requirements under 21 CFR Subpart H (drugs) or Subpart E (biologics).

The Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint Report is updated quarterly, in January, April, July, and October, providing a rolling compliance reference. The Postmarket Requirements and Commitments Database tracks the status of specific postmarket obligations, giving QA teams a structured audit trail against which internal CAPA documentation and ICH Q10 quality system reviews can be benchmarked. The addition of the Coordinating Council report under FDORA Section 3210 introduces a formal annual accountability layer that did not exist in prior cycles.

Manufacturers with products in the accelerated approval pipeline should cross-reference the next quarterly surrogate endpoint report, due in July 2026, against their current postmarket commitment schedules to confirm alignment before the next inspection cycle.

Source: FDA via What's New: Drugs RSS Feed, 15 May 2026.